For: | Kong DR, Wang JG, Sun B, Wang MQ, Chen C, Yu FF, Xu JM. β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis. World J Gastroenterol 2015; 21(23): 7191-7196 [PMID: 26109805 DOI: 10.3748/wjg.v21.i23.7191] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i23/7191.htm |
Number | Citing Articles |
1 |
E. L. Krasavtsev, A. V. Sennikova. ADRENERGIC AGENTS IN CORRECTION OF PORTAL HYPERTENSION IN CIRRHOSIS OF THE LIVER. Hepatology and Gastroenterology 2020; 4(1): 12 doi: 10.25298/2616-5546-2020-4-1-12-14
|
2 |
Pramod Kumar, Sunil Taneja, Virendra Singh. Beta‐blockers in patients with advanced liver disease: Has the dust settled?. Liver Transplantation 2017; 23(10): 1351 doi: 10.1002/lt.24831
|
3 |
Haidar A. N. Abood. Impact of 27Gln\Glu Polymorphisms of β2-Adrenergic Receptor Gene on Pulmonary Function in Asthmatic Children Treated with Nebulized Salbutamol. Biomedical and Biotechnology Research Journal (BBRJ) 2021; 5(4): 435 doi: 10.4103/bbrj.bbrj_67_21
|
4 |
Sarah Shalaby, Luisa Ronzoni, Virginia Hernandez‐Gea, Luca Valenti. The genetics of portal hypertension: Recent developments and the road ahead. Liver International 2023; 43(12): 2592 doi: 10.1111/liv.15732
|
5 |
Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Robert Schierwagen. Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. Frontiers in Medicine 2023; 9 doi: 10.3389/fmed.2022.1100966
|
6 |
Seong Hee Kang, Moon Young Kim, Soon Koo Baik. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatology International 2018; 12(S1): 112 doi: 10.1007/s12072-017-9806-1
|
7 |
Ayat Sahib Mohammed, Haidar Abdul Amir Abood, Aqeel Mehdi Hussein. The Effect of 16 Arg/Gly β2–Adrenergic Receptors Gene Polymorphism on Pulmonary Function in Asthmatic Children Treated with Nebulized Salbutamol. Biomedical and Biotechnology Research Journal (BBRJ) 2021; 5(2): 161 doi: 10.4103/bbrj.bbrj_36_21
|